Zobrazeno 1 - 10
of 157
pro vyhledávání: '"Dyagil I"'
Publikováno v:
Вісник проблем біології і медицини, Vol 2, Iss 1, Pp 229-234 (2019)
Prognostic significance of additional chromosomal abnormalities (ACAs) for tyrosinekinase inhibitors therapy (TKI) response in chronic myeloid leukemia (CML) patients is discussed. In many ways, this uncertainty is dueto the low frequency as well as
Externí odkaz:
https://doaj.org/article/7c01c14647264174b01bd0177bb0bf57
Publikováno v:
Experimental Oncology; 2023, Vol. 45 Issue 3, p322-327, 6p
Autor:
Romanenko, A., Bebeshko, V., Hatch, M., Bazyka, D., Finch, S., Dyagil, I., Reiss, R., Chumak, V., Bouville, A., Gudzenko, N., Zablotska, L., Pilinskaya, M., Lyubarets, T., Bakhanova, E., Babkina, N., Trotsiuk, N., Ledoschuk, B., Belayev, Y., Dybsky, S. S., Ron, E., Howe, G.
Publikováno v:
Radiation Research, 2008 Dec 01. 170(6), 691-697.
Externí odkaz:
https://www.jstor.org/stable/25167827
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Experimental Oncology; Sep2022, Vol. 44 Issue 3, p208-212, 5p
Publikováno v:
Experimental Oncology; Sep2021, Vol. 43 Issue 3, p224-228, 5p
Multiple myeloma (MM) remains an incurable disease, with little information available on its management in real-world clinical practice. The results of the present prospective, noninterventional observational study revealed great diversity in the tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::121f2e22d1623bbbe181c3f9a1e47032
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3085843
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3085843
Publikováno v:
Experimental Oncology; Sep2020, Vol. 42 Issue 3, p172-177, 6p
Publikováno v:
In Hematology, Transfusion and Cell Therapy October 2020 42 Supplement 1:18-19
Autor:
Chanan-Khan, Asher, Cramer, Paula, Demirkan, Fatih, Fraser, Graeme, Silva, Rodrigo Santucci, Grosicki, Sebastian, Pristupa, Aleksander, Janssens, Ann, Mayer, Jiri, Bartlett, Nancy L, Dilhuydy, Marie-Sarah, Pylypenko, Halyna, Loscertales, Javier, Avigdor, Abraham, Rule, Simon, Villa, Diego, Samoilova, Olga, Panagiotidis, Panagiots, Goy, Andre, Mato, Anthony, Pavlovsky, Miguel A, Karlsson, Claes, Mahler, Michelle, Salman, Mariya, Sun, Steven, Phelps, Charles, Balasubramanian, Sriram, Howes, Angela, Hallek, Michael, Assouline, S, Bence-Bruckler, I, Buckstein, R, Fraser, G, Larratt, L, Minuk, L, Villa, D, Angevine, A, Bartlett, N, Bixby, D, Caimi, P, Chanan-Khan, A, Craig, M, Forero-Torres, A, Ganguly, S, Goy, A, Heffner, L, Hermann, R, Lansigan, F, Leis, J, Letzer, J, Link, B, Liu, D, McCaul, K, McGuire, E, Skinner, W, Starodub, A, Stuart, R, Thirman, M, Tirumali, N, Yang, J, Janssens, A, Offner, F, Van den Neste, E, Van Hoof, A, Mayer, J, Novak, J, Trneny, M, Cartron, G, Dartigeas, C, Dilhuydy, M, Ghez, D, Haioun, C, Leblond, V, Salles, G, Balser, C, Cramer, P, Dreger, P, Durig, J, Eckart, M, Heinrich, B, Illmer, T, Jentsch-Ullrich, K, Pfreundschuh, M, Schetelig, J, Schlag, R, Soling, U, Stilgenbauer, S, Anagnostopoulos, A, Dimopoulos, A, Panagiotidis, P, Vrakidou, E, Bairey, O, Yehuda, D Ben, Braester, A, Fineman, R, Herishanu, Y, Nagler, A, Ruchlemer, R, Tadmor, T, Grosicki, S, Homenda, W, Jurczak, W, Pluta, A, Woszczyk, D, Espirito Santo, A, Luis, R, Raposo, J, Viveiros, C, Alexeeva, J, Dunaev, Y, Golubeva, M, Khuageva, N, Loginov, A, Lysenko, I, Osmanov, E, Pavlov, V, Pristupa, A, Proydakov, A, Rossiev, V, Samarina, I, Samoilova, O, Serduk, O, Shneider, T, Udovitsa, D, Voloshin, S, Gayoso, J, Gonzalez, M, Gonzalez Barca, E, Hernandez Rivas, J, Jargue, I, Loscertales, J, Karlsson, C, Sender, M, Aktan, M, Arslan, O, Demirkan, F, Ferhanoglu, B, Kaynar, L, Sayinalp, N, Vaural, F, Yagci, M, Dyagil, I, Kaplan, P, Masliak, Z, Oliynyk, H, Popovska, T, Pylypenko, H, Rekhtman, G, Dearden, C, Morley, N, Moss, P, Rule, S, Pavlovsky, M, Riveros, D, Santucci-Silva, R, Romeo, M, Scheliga, A, Salazar, L, Gomez, D, Ramirez, E, Jung, C
Most patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma relapse after initial therapy. Bendamustine plus rituximab is often used in the relapsed or refractory setting. We assessed the efficacy and safety of adding ibrutinib, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afe583710bcd15b107e94325ade65998
https://www.ncbi.nlm.nih.gov/pubmed/26655421
https://www.ncbi.nlm.nih.gov/pubmed/26655421